Contra-indicated in patients with severe renal impairment, end stage renal disease, or on dialysis.
Invokamet is canagliflozin and metformin.
- TRADE NAMES: Invokamet (Janssen); Invokana (Janssen)
- INDICATIONS: Type II diabetes mellitus
- CLASS: Antidiabetic, Sodium-glucose co-transporter 2 (SGLT2) inhibitor ('gliflozin')
- HALF-LIFE: 11–13 hours
- See adverse reactions attributed to class:
Sodium-glucose co-transporter 2 (SGLT2) inhibitor ('gliflozin')
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of canagliflozin in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 03/13/2024
